[1-(3-Tert-butyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-cyclopropyl-amine → HCID 71112662, compound
Reaction equation
[C:1]([C:3]1[CH:8]=[CH:7][C:6]([C:9]2[CH:13]=[C:12]([C:14]([OH:16])=O)[O:11][N:10]=2)=[C:5]([F:17])[CH:4]=1)#[N:2].[C:18]([C:22]1[N:26]=[C:25]([N:27]2[CH2:32][CH2:31][CH:30]([NH:33][CH:34]3[CH2:36][CH2:35]3)[CH2:29][CH2:28]2)[O:24][N:23]=1)([CH3:21])([CH3:20])[CH3:19]>>[C:18]([C:22]1[N:26]=[C:25]([N:27]2[CH2:28][CH2:29][CH:30]([N:33]([CH:34]3[CH2:36][CH2:35]3)[C:14]([C:12]3[O:11][N:10]=[C:9]([C:6]4[CH:7]=[CH:8][C:3]([C:1]#[N:2])=[CH:4][C:5]=4[F:17])[CH:13]=3)=[O:16])[CH2:31][CH2:32]2)[O:24][N:23]=1)([CH3:21])([CH3:19])[CH3:20]Participants
3
Procedure
The title compound is prepared from 3-(4-cyano-2-fluoro-phenyl)-isoxazole-5-carboxylic acid and [1-(3-tert-butyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-cyclopropyl-amine following a procedure analogous to that described in Example 18. LC (method 18): tR=1.29 min; Mass spectrum (ESI+): m/z=479 [M+H]+.
Sources & evidence
- ORD record
- ord-a9cfe9d1144c4537bf4f0a960101fb04
- Source dataset
- uspto-grants-2014_12